This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Bevenopran

Merck & Co., Inc.

Drug Names(s): ADL5945, CB-5945, OpRA III, CB5945, MK-2402

Description: ADL5945 is a potent mu opioid receptor antagonist.

Deal Structure: ADL5945 was originally developed by Eli Lilly.

Adolor and Lilly
In September 2009, Adolor announced that it has acquired from Eli Lilly the exclusive worldwide rights to ADL5945. Financial terms of the agreement include an upfront payment of $2 million to Lilly, royalties on net sales of any approved product and up to approximately $70 million in milestones contingent upon achievement of pre-defined, late-stage clinical and regulatory events and achievement of certain sales targets.

Adolor and Cubist
In October 2011, Cubist Pharmaceuticals agreed to acquire Adolor. This acquisition closed in December 2011.

Merck and Cubist
In December 2014, Merck and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash. Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also...See full deal structure in Biomedtracker

Partners: Eli Lilly & Company


Bevenopran News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug